期刊文献+

补肾通络法配合MPT化疗方案治疗老年多发性骨髓瘤18例临床观察 被引量:6

下载PDF
导出
摘要 目的:观察补肾通络中药联合MPT方案治疗老年多发性骨髓瘤临床疗效。方法:将35例老年性多发性骨髓瘤患者随机分治疗组和对照组。对照组采用常规的口服MPT化疗方案,治疗组在对照组治疗的基础上加服以补肾通络为主的中药汤剂。2组均以30d为1个疗程,6个疗程后观察疗效。结果:治疗组疗效明显好于对照组,且耐受性良好,不良反应少。结论:补肾通络中药配合MPT联合化疗方案有增效减毒作用。
机构地区 江苏省中医院
出处 《江苏中医药》 CAS 北大核心 2008年第9期38-39,共2页 Jiangsu Journal of Traditional Chinese Medicine
  • 相关文献

参考文献4

  • 1漆佩静,邱录贵.多发性骨髓瘤的新药临床研究进展[J].国际输血及血液学杂志,2006,29(5):447-450. 被引量:3
  • 2Palumbo A, Bringhen S, Musto P, et al. Oral melphalan, prednisone, and Thalidomide for multiple myeloma. Blood (ASH Annual Meeting Abstracts), 2005,106(11) :779a.
  • 3Palumbo A, Brighen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma randomized controlled trial Lancet, 2006,367 (9513 ) : 825.
  • 4Blade J, Samsom D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haematopoietic stem cell transplantation. Br J Haematol, 1998,102 : 1115.

二级参考文献21

  • 1Singhal S, Mehta J, Desikan R, et al. Antitumor activity of Thalidomide in refractory multiple myeloma. N Engl J Med, 1999,341(21):1565-1571.
  • 2Rajkumar SV,Blood E,Vesole D,et al. Phase Ⅲ Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol, 2006,24 (3) : 431-436.
  • 3Cavo M, Zamagni E, Tosi P,et al. Superiority of Thalidomide and dexamethasone over vineristine doxorubiein dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood, 2005,106 ( 1 ) : 35-39.
  • 4Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and Hematopoietic Cell Transplantation for Multiple Myeloma, N Engl J Med,2006,354(10):1021-1030.
  • 5Palumbo A, Bringhen S, Musto P, et al. Oral melphalan,prednisone, and Thalidomide for multiple myeloma. Blood (ASH Annual Meeting Abstracts),2005,106(11) :779a.
  • 6Facon T,Mary JY,Hulin C,et al. Major Superiority of Melphalan -Prednisone ( MP ) + Thalidomide ( THAL ) over MP and Autologous Stem Cell Transplantation in the Treatment of Newly Diagnosed Elderly Patients with Multiple Myeloma. Blood (ASH Annual Meeting Abstracts),2005,106(11) :780a.
  • 7Dimopoulos M A,Spencer A, Attal M ,et al: Study of Lenalidomide Plus Dexamethasone Versus Dexamethasone Alone in Relapsed or Refractory Multiple Myeloma (MM):Results of a Phase 3 Study (MM-010). Blood (ASH Annual Meeting Abstracts),2005.106(11):6a.
  • 8Rajkumar SV, Hayman SR, Lacy MQ.et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma, glood,2005,106(13):4050-4053.
  • 9Richardson PG, Barlogie B. Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Meal,2003,348(26) :2609-2617.
  • 10Jagannath S, Barlogie B, Berenson J, et al: A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol,2004,127 (2) : 165-172.

共引文献2

同被引文献75

引证文献6

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部